|
We're excited to announce a groundbreaking opportunity in the fight against cancer. Starpax has launched a Regulation A capital raise to fuel our pioneering clinical trials, aiming to revolutionize cancer treatment and offer hope to millions worldwide.Current cancer treatments struggle to reach 90% of the tumor volume. Antibodies, nanocarriers, precision targeting medicine, and even immune cells, don't reach more than 10% of the tumor volume. Join us in our mission to change the way we treat cancer. Here's why you should consider investing in Starpax's patented technology: The future of cancer treatment is here: Starpax's cutting-edge technology features Starpax Living self-propelled MagnetodronesTM, which are sensitive to special magnetic fields and carry drugs on their surface to the tumor volume. Additionally, the PolarTrak® machine generates magnetic fields that control the trajectory of the Magnetodrones™ in 3D, forcing the drugs to spread throughout the tumor volume. Cutting-edge technology: The Living Magnetodrones, guided by the PolarTrak's artificial intelligence, are injected directly into the tumor. They are forced to spread across the tumor, reaching hypoxic zones. Preclinical trials have demonstrated a 100% remission rate in extremely aggressive tumors without any side effects observed. Reduced risk, accelerated progress: Starpax minimizes trial risks and accelerates approvals with our FDA-approved anti-cancer molecules that can target six common cancers simultaneously. We meet the criteria for the FDA Fast Track Program and Health Canada accelerated review standards, which will ensure swift progress Scalable business model: Partnering with top U.S. firms, Starpax plans rapid deployment of 25 treatment centers within seven years, with forecasted EBITDA, reaching $12 billion annually upon FDA approval. Together, we can create a future where cancer treatment is more effective, safe, and accessible. Invest in Starpax today and be part of this transformative journey. The Starpax Team info@starpaxbiopharma.com  This message is a PAID ADVERTISEMENT for Starpax from Interactive Offers. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $1800. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Starpax or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Starpax on Starpax website for additional information about the relationship between Interactive Offers and Starpax. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc |
Today's Bonus Content: Rare 94.3% Options Win rate [Outrageous but True!]
Tidak ada komentar:
Posting Komentar